Compare Kyndryl Holdings Inc (KD) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Kyndryl Holdings Inc trades at $11.73 (market cap $2.67B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| KD | ORKA | |
|---|---|---|
Market Cap | $2.67B | $5.18B |
Volume | 3,966,787 | 490,798 |
Sector | Technology | Health |
52-Week High | $28.92 | $113.08 |
52-Week Low | $10.59 | $26.19 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $5.49B | $4.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.79, up slightly by 0.08% with neutral technical indicators. The company shows improving fundamentals with 2025 revenue of $15.06B and a return to profitability with $252M net income after three years of losses. Recent earnings have been mixed with two misses and one beat. Analyst consensus is cautious with 71% hold ratings, though the $14.67 price target suggests 24% upside potential from current levels.
The stock presents a turnaround story with improving cash flow and profitability, but faces execution risks amid competitive pressures. Recent AI-focused initiatives and government contracts provide growth catalysts, though the high P/E ratio of 33.08 requires strong earnings growth to justify valuation. Institutional ownership trends and technical resistance near $12 remain key watchpoints.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
